临床试验

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT：NCT03686124 · RECRUITING

NCT编号NCT03686124

状态RECRUITING

开始日期2019-05-14

SponsorImmatics US, Inc. (INDUSTRY)

First posted2018-09-26

Last updated2026-05-13

简要摘要

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。